2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Mach, F; Baigent, C; Catapano, AL; Koskinas, KC; Casula, M; Badimon, L; Chapman, MJ; De Backer, GG; Delgado, V; Ference, BA; Graham, IM; Halliday, A; Landmesser, U; Mihaylova, B; Pedersen, TR; Riccardi, G; Richter, DJ; Sabatine, MS; Taskinen, M-R; Tokgozoglu, L; Wiklund, O; Mueller, C; Drexel, H; Aboyans, V; Corsini, A; Doehner, W; Farnier, M; Gigante, B; Kayikcioglu, M; Krstacic, G; Lambrinou, E; Lewis, BS; Masip, J; Moulin, P; Petersen, S; Petronio, AS; Piepoli, MF; Pinto, X; Raber, L; Ray, KK; Reiner, Z; Riesen, WF; Roffi, M; Schmid, J-P; Shlyakhto, E; Simpson, IA; Stroes, E; Sudano, I; Tselepis, AD; Viigimaa, M; Vindis, C; Vonbank, A; Vrablik, M; Vrsalovic, M; Zamorano Gomez, JL; Collet, J-P; Cardiology, ES; Soc, EA

dc.contributor.author	Mach, F	en_US
dc.contributor.author	Baigent, C	en_US
dc.contributor.author	Catapano, AL	en_US
dc.contributor.author	Koskinas, KC	en_US
dc.contributor.author	Casula, M	en_US
dc.contributor.author	Badimon, L	en_US
dc.contributor.author	Chapman, MJ	en_US
dc.contributor.author	De Backer, GG	en_US
dc.contributor.author	Delgado, V	en_US
dc.contributor.author	Ference, BA	en_US
dc.contributor.author	Graham, IM	en_US
dc.contributor.author	Halliday, A	en_US
dc.contributor.author	Landmesser, U	en_US
dc.contributor.author	Mihaylova, B	en_US
dc.contributor.author	Pedersen, TR	en_US
dc.contributor.author	Riccardi, G	en_US
dc.contributor.author	Richter, DJ	en_US
dc.contributor.author	Sabatine, MS	en_US
dc.contributor.author	Taskinen, M-R	en_US
dc.contributor.author	Tokgozoglu, L	en_US
dc.contributor.author	Wiklund, O	en_US
dc.contributor.author	Mueller, C	en_US
dc.contributor.author	Drexel, H	en_US
dc.contributor.author	Aboyans, V	en_US
dc.contributor.author	Corsini, A	en_US
dc.contributor.author	Doehner, W	en_US
dc.contributor.author	Farnier, M	en_US
dc.contributor.author	Gigante, B	en_US
dc.contributor.author	Kayikcioglu, M	en_US
dc.contributor.author	Krstacic, G	en_US
dc.contributor.author	Lambrinou, E	en_US
dc.contributor.author	Lewis, BS	en_US
dc.contributor.author	Masip, J	en_US
dc.contributor.author	Moulin, P	en_US
dc.contributor.author	Petersen, S	en_US
dc.contributor.author	Petronio, AS	en_US
dc.contributor.author	Piepoli, MF	en_US
dc.contributor.author	Pinto, X	en_US
dc.contributor.author	Raber, L	en_US
dc.contributor.author	Ray, KK	en_US
dc.contributor.author	Reiner, Z	en_US
dc.contributor.author	Riesen, WF	en_US
dc.contributor.author	Roffi, M	en_US
dc.contributor.author	Schmid, J-P	en_US
dc.contributor.author	Shlyakhto, E	en_US
dc.contributor.author	Simpson, IA	en_US
dc.contributor.author	Stroes, E	en_US
dc.contributor.author	Sudano, I	en_US
dc.contributor.author	Tselepis, AD	en_US
dc.contributor.author	Viigimaa, M	en_US
dc.contributor.author	Vindis, C	en_US
dc.contributor.author	Vonbank, A	en_US
dc.contributor.author	Vrablik, M	en_US
dc.contributor.author	Vrsalovic, M	en_US
dc.contributor.author	Zamorano Gomez, JL	en_US
dc.contributor.author	Collet, J-P	en_US
dc.contributor.author	Cardiology, ES	en_US
dc.contributor.author	Soc, EA	en_US
dc.date.accessioned	2020-01-31T16:24:42Z
dc.date.issued	2020-01-01	en_US
dc.identifier.issn	0195-668X	en_US
dc.identifier.uri	https://qmro.qmul.ac.uk/xmlui/handle/123456789/62584
dc.format.extent	111 - 188	en_US
dc.language.iso	en	en_US
dc.relation.ispartof	EUROPEAN HEART JOURNAL	en_US
dc.subject	Guidelines	en_US
dc.subject	dyslipidaemias	en_US
dc.subject	cholesterol	en_US
dc.subject	triglycerides	en_US
dc.subject	low-density lipoproteins	en_US
dc.subject	high-density lipoproteins	en_US
dc.subject	apolipoprotein B	en_US
dc.subject	lipoprotein(a)	en_US
dc.subject	lipoprotein remnants	en_US
dc.subject	total cardiovascular risk	en_US
dc.subject	treatment (lifestyle)	en_US
dc.subject	treatment (drugs)	en_US
dc.subject	treatment (adherence)	en_US
dc.subject	very low-density lipoproteins	en_US
dc.subject	familial hypercholesterolaemia	en_US
dc.title	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)	en_US
dc.type	Article
dc.identifier.doi	10.1093/eurheartj/ehz455	en_US
pubs.author-url	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000506814800011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a	en_US
pubs.issue	1	en_US
pubs.notes	Not known	en_US
pubs.publication-status	Published	en_US
pubs.volume	41	en_US
rioxxterms.funder	Default funder	en_US
rioxxterms.identifier.project	Default project	en_US

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

NIHR Advanced Imaging [368]

Show simple item record

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Files in this item

This item appears in the following Collection(s)

Related items

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. ﻿

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes ﻿

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. ﻿

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans.